CARM (CARISMA Therapeutics) OCF Margin %: 4.22% (As of Sep. 2025)


What is CARISMA Therapeutics OCF Margin %?

CARISMA Therapeutics CARM +1.25% OCF Margin % is 4.22% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, CARISMA Therapeutics ranks better than 53.54% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. CARISMA Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2025 was $1.91 Mil. CARISMA Therapeutics's Revenue for the three months ended in Sep. 2025 was $45.25 Mil. Therefore, CARISMA Therapeutics's OCF Margin % for the quarter that ended in Sep. 2025 was 4.22%.

As of today, CARISMA Therapeutics's current OCF Yield % is -6,612.09%.

The historical rank and industry rank for CARISMA Therapeutics's OCF Margin % or its related term are showing as below:

CARM' s OCF Margin % Range Over the Past 10 Years
Min: -544.12   Med: -305.2   Max: -52.02
Current: -42.59

During the past 5 years, the highest OCF Margin % of CARISMA Therapeutics was -52.02%. The lowest was -544.12%. And the median was -305.20%.

CARM's OCF Margin % is ranked better than
53.54% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs CARM: -42.59

CARISMA Therapeutics OCF Margin % Related Terms

CARISMA Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics OCF Margin % Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
0.00 0.00 -52.02 -544.12 -305.20

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -384.64 -228.63 -269.97 0.00 4.22

CARM vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's OCF Margin % falls into.


CARISMA Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-59.917/19.632
=-305.20 %

CARISMA Therapeutics's OCF Margin for the quarter that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=1.908/45.25
=4.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 4.22% mean?
CARISMA Therapeutics (CARM) has a OCF Margin % of 4.22% as of Sep. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #446 out of 960 companies in the Biotechnology industry, placing it in the top 46.5%.
Is CARISMA Therapeutics' OCF Margin % too high?
CARISMA Therapeutics' current OCF Margin % is 4.22%. Based on the distribution chart, CARISMA Therapeutics ranks #446 out of 960 companies in the Biotechnology industry, which is above the industry midpoint.
How does CARISMA Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #446 out of 960 companies for OCF Margin %. This puts CARISMA Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current OCF Margin % is 4.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current OCF Margin % is 4.22%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current OCF Margin % is 4.22% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.